Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81
Document › Details

PeptiDream Inc.. (4/29/15). "Press Release: PeptiDream Announces Peptide Discovery Collaboration Agreement with Merck & Co., Inc". Tokyo.

Organisations Organisation PeptiDream Inc. (JP)
  Organisation 2 Merck & Co. Inc. (NYSE: MRK)
  Group Merck (US) (MSD) (Group)
Products Product Peptide Discovery Platform System (PDPS) technology
  Product 2 peptide-based drug
Person Person Kubota, Kiichi (PeptiDream 201504 CEO)

PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”) (Tokyo:4587) today announced a multi-target discovery and optimization collaboration with Merck & Co., Inc., Kenilworth, N.J., U.S.A., known as MSD outside the United States and Canada, through a subsidiary. Under the agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to generate macrocylic/constrained peptides against multiple targets of interest selected by Merck & Co. Inc. Merck & Co. Inc. will have the right to develop and commercialize all therapeutic peptides resulting from the collaboration and retains an option to nonexclusively license the PDPS technology at a future date. PeptiDream will receive an undisclosed upfront payment, research funding and will be eligible for payments associated with the achievement of certain preclinical and clinical development milestones. In addition, PeptiDream is eligible to receive royalties on sales of any products that arise from the collaboration.

“We are very excited to collaborate with Merck & Co. Inc. PeptiDream has emerged as a major player in the constrained peptide space, said Kiichi Kubota, CEO of PeptiDream Inc. Our unique PDPS platform allows us to rapidly build highly diverse constrained peptide libraries, largely tailored to the individual target, leading to the rapid identification of chemically diverse hits, which can then be quickly assessed for the desired biological activity profiles. No other technology can create such a chemically and structurally diverse set of functional and developable leads in such a short period of time”.

In the past five years, PeptiDream has established funded discovery collaborations with many leading pharmaceutical companies, such as Amgen, AstraZeneca, Bristol-Myers-Squibb, Eli Lilly, GlaxoSmithKline, Novartis, Mitsubishi Tanabe, Daiichi Sankyo, as well as a strategic collaboration with Ipsen, all of which are active and ongoing. In addition, PeptiDream has transferred its PDPS discovery platform for broad use to Bristol-Myers-Squibb and Novartis.

PeptiDream Inc
(Ticker Code:4587 TSE Mothers)

PeptiDream Inc. is a public (Tokyo Stock Exchange Mothers 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS) , a state-of-the-art highly versatile peptide generation and selection platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the discovery and development of best-in-class and first-in-class peptide-based therapeutics. PeptiDream aspires to be a world leader in the discovery and development of novel highly functional peptide therapeutics to address unmet medical needs and improve the quality of life of patients worldwide. For further information please visit


PeptiDream Inc.
Patrick C Reid +81-3-5790-9991 (Tokyo)

Record changed: 2019-06-09


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for PeptiDream Inc. (JP)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81

» top